Canada-based Sernova Biotherapeutics Inc. (TSX: SVA) and Germantown, Maryland-based Seraxis Holdings, Inc. have signed a definitive merger agreement to combine their complementary type 1 diabetes (T1D) platforms under a new entity, BetaNova Biotherapeutics, Inc., headquartered in Germantown, Maryland. The transaction pairs Sernova's clinically validated Cell Pouch Bio-hybrid Organ implant with Seraxis' stem cell-derived pancreatic islet programs and in-house current Good Manufacturing Practice (cGMP) manufacturing, with the combined company targeting a NASDAQ listing in Q1 2027.
The merger is structured as a 50/50 combination via a statutory plan of arrangement under British Columbia's Business Corporations Act, with Seraxis' legal entity renamed BetaNova. Concurrent with signing, insider shareholders of both companies committed USD 10 million in non-brokered convertible note financing, with the round open to additional qualified investors through September 30, 2026. Notes convert automatically into non-voting BetaNova common stock at closing. The company said the proceeds are intended to fund cGMP manufacturing of SR-02, first-in-human dosing in Q1 2027, and an investigational new drug (IND) submission for SR-03 in H2 2027. A break fee of USD 5 million applies in certain termination scenarios. The merger requires approval of at least 66⅔% of Sernova shareholders and is expected to close in November 2026, subject to court and Toronto Stock Exchange (TSX) approvals.
BetaNova's pipeline centers on two stem cell-derived allogeneic islet programs. SR-02, an allogeneic pancreatic endocrine cell cluster therapy, carries an FDA-cleared IND (NCT07581197) and is paired with low-toxicity immune suppressants aimed at establishing tolerance and eventually eliminating chronic immunosuppression. SR-03 adds gene edits to SR-02 designed to confer immune evasion without immunosuppression; IND submission is targeted for H2 2027. Both programs are intended for delivery via Sernova's Cell Pouch, a retrievable subcutaneous scaffold with more than 30 years of cumulative patient safety data and a completed Phase I/II study in which all primary and secondary endpoints were met. Sernova has also provided notice of termination of its iPSC development program with Evotec GmbH, effective three months after the notice date.
The immune-evasion challenge BetaNova's SR-03 is designed to address has become the defining competitive question in the field. In March 2026, Sana Biotechnology reported 14-month survival of hypoimmune islet cells without immunosuppression in a T1D patient, establishing a clinical benchmark for gene-edited approaches. Separately, NewcelX and Eledon Pharmaceuticals are pursuing a related strategy combining stem cell-derived islet replacement with immune modulation — NewcelX itself formed through a merger of two cell therapy companies.
Spot something wrong? Report an issue with this article